biotechnology · asia
RAG-17’s First-in-Human Trial Published in Nature Medicine, Marking a Small Step for the RNAi Pathway in SOD1 ALS
Early data from six patients show that this intrathecally administered siRNA conjugate drug can reduce cerebrospinal fluid SOD1 and blood neurofilament light chain; but the sample is extremely small, open-label, and does not yet support conclusions on efficacy. The next step will be the real test of its clinical value.
For amyotrophic lateral sclerosis (ALS), delivering therapeutic molecules into the central nervous system and precisely suppressing a disease-causing protein has always been an engineering challenge more difficult than the concept itself. Nature Medicine has published the first-in-human phase 1 data for RAG-17, adding an early clinical signal for RNA interference therapy in SOD1-mutant ALS: the drug appears able to enter the target environment and produce measurable changes in biomarkers.
RAG-17 is an oligonucleotide-siRNA conjugate drug designed to silence SOD1 mRNA and reduce production of mutant SOD1 protein. This type of ALS accounts for a small share of overall cases, but because the disease-causing gene is clearly defined, it has long been viewed as one of the neurodegenerative disease settings in which nucleic acid drugs have the best chance of being validated first.
According to the Nature Medicine paper abstract and Ractigen Therapeutics’ announcement on the same day, this first-in-human, open-label, dose-escalation trial enrolled six patients with SOD1-mutant ALS, who received multiple intrathecal injections of RAG-17. ClinicalTrials.gov registration data show that the trial number is NCT05903690, led by Beijing Tiantan Hospital with Ractigen as a collaborator. The study began on May 24, 2023, and was completed on July 11, 2024.
On safety, the study met its primary safety endpoint. The company announcement said that, as of the data cutoff, no serious adverse events had been observed, and no patients had received invasive mechanical ventilation. However, an early, uncontrolled trial in six people can only preliminarily rule out obvious safety signals; it cannot characterize rarer risks or tolerability after long-term repeated dosing.
The more closely watched findings relate to pharmacodynamic biomarkers. Ractigen said that in the study, the maximum mean reduction in cerebrospinal fluid SOD1 reached 69%, and the maximum mean reduction in plasma neurofilament light chain (NfL) reached 62%. The former is more closely tied to the drug’s molecular mechanism of action, while the latter is commonly used as an indicator of neuroaxonal injury. Their decline in the same direction supports that RAG-17 did indeed produce the expected biological effect in the central nervous system.
But these results still do not mean clinical efficacy has been proven. The trial had no placebo group, patients’ baseline disease courses and natural progression may differ substantially, and ALS endpoints such as functional scales, respiratory function, and survival usually require larger samples and longer follow-up to assess. In other words, the significance of this paper is not that it announces a new drug has already succeeded, but that it provides a basis for subsequent choices around dose, dosing frequency, and clinical endpoints.
Ractigen also describes RAG-17 as an SOD1 mRNA-targeting siRNA therapy entering phase 2 development, and emphasizes its SCAD central nervous system delivery platform. The next questions will be closer to the clinical setting: whether reductions in SOD1 and NfL can translate into changes in the pace of deterioration in muscle strength, respiration, and daily function; whether repeated intrathecal dosing can be tolerated by patients over the long term; and whether this RNAi pathway can offer clear differentiation in the SOD1-ALS field, where antisense oligonucleotide therapy already exists.